Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $181000.0.

  • Kymera Therapeutics' Capital Expenditures rose 19576.72% to $181000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 9031.33%. This contributed to the annual value of $12.8 million for FY2024, which is 6276.68% down from last year.
  • Latest data reveals that Kymera Therapeutics reported Capital Expenditures of $181000.0 as of Q3 2025, which was up 19576.72% from $695000.0 recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Capital Expenditures high stood at $11.6 million for Q4 2023, and its period low was -$189000.0 during Q3 2024.
  • For the 5-year period, Kymera Therapeutics' Capital Expenditures averaged around $2.8 million, with its median value being $695000.0 (2025).
  • Per our database at Business Quant, Kymera Therapeutics' Capital Expenditures surged by 301662.2% in 2023 and then plummeted by 10233.97% in 2024.
  • Kymera Therapeutics' Capital Expenditures (Quarter) stood at $501000.0 in 2021, then fell by 25.55% to $373000.0 in 2022, then surged by 3016.62% to $11.6 million in 2023, then crashed by 91.95% to $936000.0 in 2024, then tumbled by 80.66% to $181000.0 in 2025.
  • Its last three reported values are $181000.0 in Q3 2025, $695000.0 for Q2 2025, and $467000.0 during Q1 2025.